Helicobacter pylori treatment in the era of increasing antibiotic resistance
Top Cited Papers
- 4 June 2010
- Vol. 59 (8), 1143-1153
- https://doi.org/10.1136/gut.2009.192757
Abstract
With few exceptions, the most commonly recommended triple Helicobacter pylori regimen (proton pump inhibitor (PPI), amoxicillin and clarithromycin) now provides unacceptably low treatment success. A review of worldwide results suggests that successful eradication using a triple regimen is not consistently observed in any population. Clinicians should use ‘only use what works locally’ and ignore consensus statements and society guidelines if they are not consistent with local results. Clinical trials should be result based, with the goal of identifying regimens with >90–95% success. New treatments should be only be compared with the currently locally effective treatment (>90%) or a historical untreated control (which has been shown to reliably yield 0% eradication); trials using placebos or treatments known to be inferior are with rare exceptions unethical. If a highly effective regimen is not available locally, we recommend trying a 14 day concomitant quadruple treatment regimen containing a PPI, amoxicillin, clarithromycin and a nitroimidazole; 10 day sequential treatment (PPI plus amoxicillin for 5 days followed by a PPI, clarithromycin and a nitroimidazole for 5 days); or 14 day bismuth-containing quadruple treatments. Treatments needing further evaluation include those containing furazolidone or nitazoxanide, hybrids of sequential–concomitant therapies and amoxicillin–PPI dual therapy with PPI doses such that they maintain intragastric pH >6.Keywords
This publication has 98 references indexed in Scilit:
- Sequential and Concomitant Therapy With Four Drugs Is Equally Effective for Eradication of H pylori InfectionClinical Gastroenterology and Hepatology, 2010
- Efficient Identification and Evaluation of Effective Helicobacter pylori TherapiesClinical Gastroenterology and Hepatology, 2009
- Effect of eradication of Helicobacter pylori on incidence of metachronous gastric carcinoma after endoscopic resection of early gastric cancer: an open-label, randomised controlled trialThe Lancet, 2008
- Efficacy of a New Therapeutic Regimen Versus Two Routinely Prescribed Treatments for Eradication of Helicobacter Pylori: A Randomized, Double-Blind Study of Doxycycline, Co-Amoxiclav, and Omeprazole in Iranian PatientsDigestive Diseases and Sciences, 2008
- New concepts of resistance in the treatment of Helicobacter pylori infectionsNature Clinical Practice Gastroenterology & Hepatology, 2008
- One Week of Esomeprazole Triple Therapy vs. 1 Week of Omeprazole Triple Therapy Plus 3 Weeks of Omeprazole for Duodenal Ulcer Healding in Helicobacter pylori-Positive PatientsDigestive Diseases and Sciences, 2007
- Gene expressionin vivoshows thatHelicobacter pyloricolonizes an acidic niche on the gastric surfaceProceedings of the National Academy of Sciences of the United States of America, 2007
- Helicobacter pylori is invasive and it may be a facultative intracellular organismCellular Microbiology, 2007
- Sequential therapy using high-dose esomeprazole-amoxicillin followed by gatifloxacin for Helicobacter pylori infectionAlimentary Pharmacology & Therapeutics, 2006
- Helicobacter pylori eradication versus prokinetics in the treatment of functional dyspepsia: a randomized, double-blind studyThe Esophagus, 2006